MA54821A - Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques - Google Patents

Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques

Info

Publication number
MA54821A
MA54821A MA054821A MA54821A MA54821A MA 54821 A MA54821 A MA 54821A MA 054821 A MA054821 A MA 054821A MA 54821 A MA54821 A MA 54821A MA 54821 A MA54821 A MA 54821A
Authority
MA
Morocco
Prior art keywords
survival
exposure
response
methods
protection against
Prior art date
Application number
MA054821A
Other languages
English (en)
Inventor
Gary Eichenbaum
Sanchita Ghosh
Alfred Tonelli
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA54821A publication Critical patent/MA54821A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/196Thrombopoietin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA054821A 2019-01-25 2020-01-24 Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques MA54821A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962796728P 2019-01-25 2019-01-25

Publications (1)

Publication Number Publication Date
MA54821A true MA54821A (fr) 2021-12-01

Family

ID=69740564

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054821A MA54821A (fr) 2019-01-25 2020-01-24 Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques

Country Status (11)

Country Link
US (2) US20200237872A1 (fr)
EP (1) EP3914281A1 (fr)
JP (1) JP2022519196A (fr)
KR (1) KR20210119469A (fr)
CN (1) CN113660943A (fr)
AU (1) AU2020210869A1 (fr)
CA (1) CA3127458A1 (fr)
IL (1) IL285092A (fr)
MA (1) MA54821A (fr)
MX (1) MX2021008928A (fr)
WO (1) WO2020154637A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020211412A1 (en) * 2019-01-25 2021-08-12 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
WO2023056444A1 (fr) * 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Procédés d'augmentation de la production de cellules progénitrices
WO2024095178A1 (fr) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Mimétique de thrombopoïétine destiné à être utilisé dans le traitement d'une insuffisance hépatique aiguë

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025221A1 (fr) 1992-06-11 1993-12-23 Alkermes Controlled Therapeutics, Inc. Systeme d'apport de medicament sous forme d'erythropoietine
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
SG131110A1 (en) 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
EP1984014B1 (fr) 2006-02-14 2014-08-06 Janssen Pharmaceutica NV Utilisation de composés peptidiques tpo et des compositions pharmaceutiques correspondantes dans le traitement de l'anémie
AU2009256465B2 (en) 2008-06-03 2015-05-14 Janssen Pharmaceutica Nv TPO mimetic peptide for preventing hematological disorder associated with cancer treatment
SG10201603059YA (en) * 2012-05-09 2016-05-30 Cantex Pharmaceuticals Inc Treatment Of Myelosuppression
US20140051631A1 (en) * 2012-08-17 2014-02-20 Francoise Porteu Pharmaceutical composition comprising tpo or an agonist of the tpo receptor
JP6150374B2 (ja) * 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法

Also Published As

Publication number Publication date
US20220168392A1 (en) 2022-06-02
CA3127458A1 (fr) 2020-07-30
KR20210119469A (ko) 2021-10-05
AU2020210869A1 (en) 2021-08-19
IL285092A (en) 2021-09-30
WO2020154637A1 (fr) 2020-07-30
JP2022519196A (ja) 2022-03-22
WO2020154637A9 (fr) 2020-08-27
US20200237872A1 (en) 2020-07-30
CN113660943A (zh) 2021-11-16
EP3914281A1 (fr) 2021-12-01
MX2021008928A (es) 2021-11-04

Similar Documents

Publication Publication Date Title
MA54821A (fr) Méthodes pour augmenter la protection contre les lésions des organes et des vaisseaux, la récupération hématopoïétique et la survie en réponse à une exposition à une irradiation corporelle totale ou à des agents chimiques
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
UY35281A (es) Composiciones que incluyen agentes para conferir carácter hidrofóbico y estabilizantes y métodos para elaborar y usar los mismos
CL2017002994A1 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
IL251118A0 (en) An essentially water-free formulation containing at least one spore-forming fungal biological control agent, trisiloxane-adapted polyether and fumed or submerged silica
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
CL2012002026A1 (es) Compuestos derivados de amidas, inhibidores de hdac6; composicion farmaceutica que los comprende; kit farmaceutico;utiles en el tratamiento del cancer, artritis reumatoide, colitis ulcerativa, enfermedad de crohn, lupus eritematoso,sistemico, entre otras.
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
DK3143090T3 (da) Blæk kompositioner til tredimensional printning og fremgangsmåder til at danne genstande ved brug af førnævnte blæk kompositioner
MA45407A (fr) Compositions et méthodes de déplétion de cellules
MA54411A (fr) Compositions contenant de l'ibrutinib
CO6950476A2 (es) Derivados de 8-carbamoil-2-(2,3- pirid- 6- ilo di sustituido) -1,2,3,4 -tetrahidroisoquinolina como agentes inductores de la apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes
DK3233129T3 (da) Nukleinsyrekonstrukter og genterapivektorer til anvendelse i behandlingen af wilsons sygdom og andre lidelser
BR112018005208A2 (pt) Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana
ITUB20155622A1 (it) Dispositivo e procedimento per la manipolazione di articoli come imballaggi multipli, collettami o simili
DK3114215T3 (da) Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
MA45046A (fr) Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules
DK3086784T3 (da) Bicalutamid analoger eller (s)-bicalutamid som exocytose aktiverende forbindelser til brug i behandling af lysosomal lagringssygdom eller glycogenose
DK3253766T3 (da) Forbindelser og fremgangsmåder til forebyggelse eller behandling af sansehårscelledød
MA44601A (fr) Composition ophtalmique contenant de la pvp-i
MA51823A (fr) Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules
MA43978A (fr) Dérivé de sulfonamide hétérocyclique et médicament le contenant
DK3509595T3 (da) Formuleringer af hydroxypyridonat-actinid/lanthanid-dekorporeringsmidler